Saroja Pharma Industries India MD, chairman, board of directors and AGM
NSE: SAROJAChemicals & Petrochemicals
Share price at the NSE close on 19 Oct 2026. Previous close ₹40.80.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price.
- ₹16 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 30 May 2026
- 10.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 30 May 2026
- 0.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 30 May 2026
- 9.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 30 May 2026
- 0.83
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,600100.0% delivered
Saroja Pharma Industries India board of directors
At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- Pravin Chandak & Associates'Peer-review certificate valid to Nov 2027
1 earlier auditor
- Praveen Chandak & AssociatesNamed in the filing for the quarter to Mar 2025
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Saroja Pharma Industries India AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Saroja Pharma Industries India share news and announcements
Annual general meeting, 30 Sep 2026
395 shareholders on the register on 23 Sep 2026; present: 4 promoters and 3 others; votes counted by HEMANT MAHESHWARI / H.MAHESHWARI ASSOCIATES.The company's voting result (opens in a new tab)
- Adoption of Audited Financial Statements for FY ended March 31, 2026, together with Reports of Board of Directors and Auditors thereon.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 74.32% · promoters 98.67% · institutions 0.00% · other public 8.41%
- Re-appointment of Mr. Pulinattu Damodaran Nandakumar as Director, retiring by rotation.OrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 74.32% · promoters 98.67% · institutions 0.00% · other public 8.41%
- Re-designation of Mr. Pulinattu Damodaran Nandakumar from Non-Executive Director to Whole-time Director for 5 years.OrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 74.32% · promoters 98.67% · institutions 0.00% · other public 8.41%
- Regularisation of Mr. Santosh Shivram Palav as Director.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 74.32% · promoters 98.67% · institutions 0.00% · other public 8.41%
- Appointment of Mr. Ravindra Shivaji Salaskar as Director and Whole-time Director for 5 years.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 74.32% · promoters 98.67% · institutions 0.00% · other public 8.41%
- Remuneration approval for Mr. Salaskar (no profit/inadequate profit case)Special100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 74.32% · promoters 98.67% · institutions 0.00% · other public 8.41%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Sep 2025. The company's results filing for the quarter to Mar 2026 says no statement of how money raised was used applies to it.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere |
|---|---|---|---|---|---|
| Public IssuesSep 2023 | 9.11 | To Set-up a Manufacturing Unit | 7.05 | 7.05 | No |
| Public IssuesSep 2023 | 9.11 | To repay the unsecured loan of the Company | 1.75 | 1.75 | No |
| Public IssuesSep 2023 | 9.11 | Public issue related expenses | 0.31 | 0.31 | No |